1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Rubella (German Measles) - Drugs In Development, 2022, provides an overview of the Rubella (German Measles) (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Rubella also known as the German measles is an acute, contagious viral infection. The rubella virus is transmitted by airborne droplets when infected people sneeze or cough. Symptoms include fever, headache, stuffy or runny nose, inflamed, red eyes, aching joints and enlarged, tender lymph nodes at the base of the skull, the back of the neck and behind the ears.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Rubella (German Measles) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Rubella (German Measles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Rubella (German Measles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rubella (German Measles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 3, 1, 2 and 2 respectively. Similarly, the Universities portfolio in Phase III stages comprises 2 molecules, respectively.
Rubella (German Measles) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Rubella (German Measles) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Rubella (German Measles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rubella (German Measles) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rubella (German Measles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rubella (German Measles) (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rubella (German Measles) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rubella (German Measles) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Rubella (German Measles) - Overview
- Rubella (German Measles) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Rubella (German Measles) - Therapeutics Assessment
- Assessment by Route of Administration
- Assessment by Molecule Type
- Rubella (German Measles) - Companies Involved in Therapeutics Development
- Amogen Pharma Pvt Ltd
- Beijing Minhai Biotechnology Co Ltd
- Daiichi Sankyo Co Ltd
- Enesi Pharma Ltd
- Indian Immunologicals Ltd
- Micron Biomedical Inc
- Sinovac Biotech Ltd
- Vaxxas Inc
- Zhongyianke Biotech Co Ltd
- Zydus Lifesciences Ltd
- Rubella (German Measles) - Drug Profiles
- (measles + mumps + rubella + varicella) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- (measles + mumps + rubella + varicella) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- (measles + mumps + rubella) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- (measles + mumps + rubella) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- (measles + mumps + rubella) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- (measles + rubella) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- (measles + rubella) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- (measles + rubella) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- (measles + rubella) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- (measles [strain Edmonstons-Zagreb] + rubella [strain RA-27]) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- BK-1601 - Drug Profile
- Product Description
- Mechanism Of Action
- rubella vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- VN-0102 - Drug Profile
- Product Description
- Mechanism Of Action
- Rubella (German Measles) - Dormant Projects
- Rubella (German Measles) - Product Development Milestones
- Featured News & Press Releases
- May 05, 2021: Enesi Pharma achieves key milestone in development of thermostable solid-dose live vaccines against measles and rubella
- Mar 18, 2020: Vaxxas awarded US$5 million grant for clinical study of measles and rubella vaccination
- Nov 30, 2019: Vaxxas was awarded research and development fund of USD 4,997,693 from Bill & Melinda Gates Foundation
- Nov 30, 2016: Vaxxas was awarded research and development fund of USD 4,479,552 from Bill & Melinda Gates Foundation
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Rubella (German Measles), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Rubella (German Measles) - Pipeline by Amogen Pharma Pvt Ltd, 2022
- Rubella (German Measles) - Pipeline by Beijing Minhai Biotechnology Co Ltd, 2022
- Rubella (German Measles) - Pipeline by Daiichi Sankyo Co Ltd, 2022
- Rubella (German Measles) - Pipeline by Enesi Pharma Ltd, 2022
- Rubella (German Measles) - Pipeline by Indian Immunologicals Ltd, 2022
- Rubella (German Measles) - Pipeline by Micron Biomedical Inc, 2022
- Rubella (German Measles) - Pipeline by Sinovac Biotech Ltd, 2022
- Rubella (German Measles) - Pipeline by Vaxxas Inc, 2022
- Rubella (German Measles) - Pipeline by Zhongyianke Biotech Co Ltd, 2022
- Rubella (German Measles) - Pipeline by Zydus Lifesciences Ltd, 2022
- Rubella (German Measles) - Dormant Projects, 2022
- Number of Products under Development for Rubella (German Measles), 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amogen Pharma Pvt Ltd
- Beijing Minhai Biotechnology Co Ltd
- Daiichi Sankyo Co Ltd
- Enesi Pharma Ltd
- Indian Immunologicals Ltd
- Micron Biomedical Inc
- Sinovac Biotech Ltd
- Vaxxas Inc
- Zhongyianke Biotech Co Ltd
- Zydus Lifesciences Ltd
